Has Kwabena Ayesu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $27,575,524 in general payments to Kwabena Ayesu, MD across 3,998 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kwabena Ayesu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kwabena Ayesu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kwabena Ayesu, MD

Internal Medicine · Orlando, FLNPI 1225019284

Payments from drug & device makers

$27,575,524in general payments, 2019–2025

Across 3,998 payments — averaging $6897.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$3.9M
Astrazeneca UK Limited$3.6M
AbbVie$2.9M
E.r. Squibb & Sons, L.L.C.$2.4M
Amgen$2.2M
Eli Lilly$1.4M
plus $11.1M from 47 others

$264,195in research payments, 2019–2025

Across 18 payments — averaging $14,677 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$137K
Celltrion, Inc.$92K
Vifor (international) Ltd.$34K
CSL Behring$358

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	332	$3,863,256
Astrazeneca UK Limited	19	$3,635,112
AbbVie(2 entities)	1,021	$2,922,091
E.r. Squibb & Sons, L.L.C.	39	$2,443,108
Amgen(2 entities)	6	$2,214,101
Eli Lilly	9	$1,444,893
Boehringer Ingelheim International GmbH	228	$1,212,373
GSK	327	$1,198,360
Genentech, Inc.	63	$1,113,997
Sanofi US Services Inc.	155	$1,053,770
Sumitomo Pharma America, Inc.	311	$866,337
Sunovion Pharmaceuticals Inc.	479	$775,581
CSL Behring	71	$651,868
AstraZeneca(2 entities)	21	$584,493
Gilead	242	$562,463
Boehringer Ingelheim	17	$409,635
Beigene, Ltd.	32	$399,684
Janssen Research & Development, LLC	118	$392,529
Astrazeneca AB	1	$317,751
Kadmon Corporation LLC	5	$167,567
Vertex	3	$161,386
Regeneron	50	$127,882
Takeda Pharmaceuticals U.S.A., Inc.	78	$85,918
Biogen	2	$83,521
Shire North American Group Inc	38	$80,899
Novartis	3	$77,467
Bausch Health US, LLC	25	$70,989
Myovant Sciences GmbH	61	$68,263
Bristol Myers Squibb	14	$63,951
Radius Health, Inc.	27	$63,147
Sanofi	12	$52,324
EMD Serono, Inc.	29	$49,461
Merck	2	$49,330
Intercept Pharmaceuticals, Inc.	14	$42,542
Chiesi USA, Inc.	9	$40,527
Adamis Pharmaceuticals Corporation	15	$35,242
Incyte Corporation	5	$31,029
Boehringer Ingelheim Canada Ltd.ltee	47	$28,369
Myovant Sciences Inc.	19	$24,891
Kiniksa Pharmaceuticals International, PLC	10	$23,356
UCB SA	1	$16,127
Beigene USA, Inc.	2	$15,285
Boehringer Ingelheim RCV GmbH & Co KG	11	$11,105
Sanofi Pasteur Inc.	2	$9,400
Viiv Healthcare Company	1	$7,800
Ferring International Pharmascience Center US	1	$6,757
Vifor (international) Ltd.	3	$4,830
Bayer	3	$3,875
Ironwood Pharmaceuticals, Inc	1	$2,923
Roche Products Limited	1	$2,566
Beigene Switzerland GmbH	1	$2,250
Biohaven Pharmaceutical Holding Company Ltd.	2	$1,600
Argenx US, Inc.	10	$1,544

How this compares

$27,575,524 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024

$70,045

Medicare patients

191

Services billed

728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Orlando

Malisa AgardOrlando$12.2M
Alfonso Gonzalez-RodriguezOrlando$4.7M
Tatyana MiroshnikovaOrlando$4.2M
Yaneicy Gonzalez RojasCoral Gables$93.5M
Juan Carlos RondonHollywood$66.8M
Jaynier MoyaPembroke Pines$45.4M
Mark KutnerMiami$35.7M
Gilberto JimenezHialeah$35.6M
Mira BaronWest Palm Beach$29.6M
William SanchezHialeah$28.9M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →